CYP2D6 Metabolizer Status and Mortality in Metoprolol Users Authors: Simon de Denus, Essaïd Oussaïd, Maxime Meloche, Antoine‐Xavier Bertrand, Grégoire Leclair, Marie‐Christyne Cyr, Martin Jutras, Marie‐Josée Gaulin, Ian Mongrain, David Busseuil, Jean‐Claude Tardif, Marie‐Pierre Dubé Published: 2026 ABSTRACT ABSTRACTNumerous pharmacogenomic (PGx) associations of pharmacokinetics and pharmacodynamics of commonly prescribed medications have been reported. Yet, the evidence supporting their association on survival remains underexamined. We sought to investigate the CYP2D6‐metoprolol association and determine whether the established variability in drug exposure and hemodynamic response would translate into differences in mortality across metabolizer status in the Montreal Heart Institute Hospital Cohort. Single random plasma samples were collected from 996 patients receiving metoprolol tartrate. Bioanalytical quantification was performed via liquid chromatography–tandem mass spectrometry, while CYP2D6 metabolizer status was based on standardized classifications. Cox regression models adjusted for age, sex, cardiovascular history, concomitant medications, and CYP2D6 inhibitors were used to assess the time to death since enrolment. Overall, 24.3% (n = 242) of patients were deceased at follow‐up (median 101.4 months). Higher metabolizer status at CYP2D6 was associated with lower risk of death (HR = 0.82, 95% CI: 0.67–0.99; p = 0.04). Metoprolol concentrations were no longer associated with mortality after adjusting for possible confounders. Our study suggests that CYP2D6‐inferred metabolizer status can inform on mortality risk in patients treated with metoprolol. Larger initiatives are required to confirm the association of CYP2D6 metabolizer status with clinical events beyond pharmacokinetic and hemodynamic considerations.Keywords: biobanks, cytochrome P450 enzymes, outcomes, personalized medicine, pharmacogenomics Introduction Pharmacogenomics (PGx) consists primarily of leveraging an individual's genomic profile to optimize its treatment response and minimize adverse drug reactions. Over the past decade, numerous gene‐drug associations have been discovered [1]. Accordingly, global networks like the Clinical Pharmacogenetics Implementation Consortium (CPIC) have published prescribing recommendations based on established pharmacogenes, of which most are drug‐metabolizing enzymes like cytochromes P450 (CYPs), as well as membrane transporters and target receptors [2, 3]. The implementation of certain PGx associations of cardiovascular therapeutics has shown potential benefits owing to improved patient outcomes relative to standard treatment approaches in practice [3]. Considering that cardiovascular disorders remain a leading cause of mortality and disability worldwide [4], PGx‐guided treatment strategies continue to hold considerable promise. Beta‐blockers are among the most commonly prescribed drug classes [5]. These agents are recommended for multiple cardiovascular disorders, including coronary artery disease and heart failure (HF) with reduced ejection fraction. Notably, metoprolol is a selective lipophilic β1‐adrenergic receptor antagonist that undergoes extensive metabolism through the highly polymorphic CYP2D6 hepatic enzyme [6]. The genetic variability of CYP2D6 is demonstrated to cause significant changes in metoprolol pharmacokinetics [7]. Moreover, multiple investigations show these inter‐individual metabolic differences across various clinical settings to translate into changes in metoprolol pharmacodynamics, such as resting heart rate and blood pressure, along with differences in the risk of bradycardia [1, 8, 9]. Although the influence of CYP2D6 on metoprolol pharmacokinetics and pharmacodynamics is well demonstrated, its impact on long‐term survival in cardiovascular cohorts is unclear. In particular, the CPIC prescribing guidelines on β‐blocker therapies have recently stated a lack of clinical evidence on patient outcomes for PGx‐guided recommendations [1]. Our group has previously shown that single random plasma samples collected as part of a large observational biobank could be leveraged to identify drug‐gene associations impacting drug concentrations and pharmacodynamic markers [10]. The present study further investigated data from the Montreal Heart Institute (MHI) Hospital Cohort to assess the impact of CYP2D6‐inferred metabolizer status on all‐cause mortality in patients receiving metoprolol. Methods Study Design and Participants This study comprised participants from the MHI Hospital Cohort, the methods of which have been described previously, including patient enrollment, data collection, and sample storage protocols [10]. Briefly, the MHI Hospital Cohort is a longitudinal hospital‐based cohort. Following informed consent from participants, trained personnel collect their medical, nutritional, psychosocial, sociodemographic, and lifestyle data. Biological samples are obtained from a single baseline blood draw. Clinical updates are obtained through hospital record linkages and follow‐up interviews are conducted every 4 years. As previously described, our study included self‐reported “White” males and females aged ≥ 18 years who reported taking oral metoprolol at baseline, regardless of daily dose or indication [10]. Liver transplant recipients were excluded [10, 11]. Patients were selected on the basis of them already having plasma samples collected at the baseline visit. Overall, 1007 metoprolol users were initially included. Of these, eight participants had incomplete data, whereas three others showed triallelic genotyping results; therefore, preventing definitive phenotype assignment. Consequently, 996 participants were thus included in this analysis. In Canada, immediate‐release metoprolol tablets are available in three strengths containing 25, 50 and 100 mg of metoprolol tartrate per tablet, while sustained‐release metoprolol is available in strengths of 100 and 200 mg of metoprolol tartrate per tablet. Concentrations of metoprolol are reported in weight of metoprolol tartrate per volume of plasma (ng/mL), as per our previous investigations [10, 12, 13]. Analyte quantification was performed at the bioanalytical laboratory of the Biopharmacy Platform at the Université de Montréal [10]. Plasma concentration levels of metoprolol tartrate equivalents were quantified by liquid chromatography–tandem mass spectrometry, with a validated range between 1 and 1000 ng/mL. Genotyping of the study participants was conducted at the Université de Montréal Beaulieu‐Saucier Pharmacogenomics Centre [10]. Allelic variants of interest, as categorized according to the PharmVar database [14], included CYP2D6*1, *2, *3, *4, *6, *7, *8, *9, *10, *11, *12, *14, *15, *17, *19, *20, *29, *41, *69, and *109, while copy number variants (CNVs) were assessed using specifically designed probes. Metabolizer status for each participant was assigned using the standardized classification of CYP2D6 genotype‐inferred phenotypes as previously described [15]. Study Outcomes All‐cause mortality was defined as the primary outcome. The association between metoprolol concentrations and CYP2D6 metabolizer status with all‐cause mortality was investigated in separate models. Statistical Analyses Descriptive analyses of the participants' clinical and genetic characteristics were performed using proportions and frequencies for categorical variables, and means and standard deviations for continuous variables, respectively. We conducted survival analyses using univariable and multivariable Cox regression models to test the associations between metoprolol tartrate concentrations, CYP2D6‐inferred metabolizer status, and time to death. Kaplan–Meier estimators modeled survival functions of each metabolizer subgroup, as appropriate. Adjustment variables for Cox analyses were selected as potential confounders according to their clinical and therapeutic relevance, including metoprolol tartrate daily dose, age, sex, resting heart rate, history of myocardial infarction, HF, atrial flutter or atrial fibrillation, hypertension, concomitant heart rate‐lowering drugs, bodyweight, and CYP2D6 moderate and strong inhibitors. All tests were two‐sided with a significance threshold of p < 0.05. Analyses were conducted using the SAS software version 9.4. Ethics Approval The MHI Hospital Cohort protocol was approved by the institution's Scientific and Ethics Committees. All participants provided written informed consent before inclusion in the MHI Hospital Cohort. The main study and amendments were also approved by the MHI's Scientific and Ethics Committees. Results Study Population Baseline cohort characteristics are described in Table S1 and are representative of this high‐risk cardiovascular cohort, with polymedicated patients presenting multiple comorbidities and prior interventions. Notably, 27% of participants were female while average values for age, bodyweight, and daily metoprolol dose were 66.5 ± 8.7 years, 84.3 ± 17.0 kg, and 84.3 ± 57.0 mg, respectively. The pharmacogenetic‐predicted metabolizer profile distribution reflected prior observations from the literature of poor (PM), intermediate (IM), normal (NM), and ultra‐rapid metabolizer (UM) status with 44 (4%), 342 (34%), 542 (54%), and 68 (7%) patients, respectively. General characteristics of participants were similar across groups. Overall, 242 patients (24.3%) were deceased at follow‐up (median 101.4 months). Association Between All‐Cause Mortality With CYP2D6 Metabolizer Status, and Metoprolol Concentrations CYP2D6 Metabolizer Groups The crude model using CYP2D6 metabolizer status as the variable of interest showed no significant difference with the participants' survival (HR = 0.941 [95% CI: 0.780–1.134]; p = 0.52). Yet, when adjusting for possible confounders, CYP2D6 metabolizer status was significantly associated with mortality (HR = 0.816 [95% CI: 0.673–0.991]; p = 0.04). More specifically, increases in the level of CYP2D6 metabolizer status, showing higher enzymatic activity, were associated with reduced mortality (Table 1). When comparing metabolizer status groups, NM and UM had lower risk of mortality than PM and IM (Table S2; HR = 0.759 [95% CI: 0.580–0.994]; p = 0.045). TABLE 1Associations between CYP2D6 genotype‐inferred metabolizer status and all‐cause mortality.VariablesModel 1Model 2Model 3Model 4Model 5Model 6Model 7HR (95% CI) p HR (95% CI) p HR (95% CI) p HR (95% CI) p HR (95% CI) p HR (95% CI) p HR (95% CI) p Inferred CYP2D6 metabolizer group0.941 (0.780–1.134)0.523 0.902 (0.747–1.088) 0.280 0.914 (0.756–1.105) 0.3530.861 (0.711–1.043)0.1260.858 (0.708–1.038)0.116 0.842 (0.694–1.020) 0.079 0.816 (0.673–0.991) 0.040 Metoprolol daily dose——1.004 (1.002–1.006) < 0.001 1.004 (1.002–1.006) < 0.001 1.004 (1.002–1.006) < 0.001 1.004 (1.003–1.006) < 0.001 1.004 (1.002–1.006) < 0.001 1.003 (1.002–1.005) 0.001 Age———— 1.072 (1.052–1.092) < 0.001 1.078 (1.058–1.098) < 0.001 1.076 (1.056–1.097) < 0.001 1.074 (1.053–1.095) < 0.001 1.076 (1.055–1.097) < 0.001 Sex————0.660 (0.486–0.896) 0.008 0.638 (0.470–0.867) 0.004 0.617 (0.448–0.850) 0.003 0.609 (0.442–0.839) 0.002 0.711 (0.512–0.985) 0.040 Resting heart rate——————1.027 (1.015–1.040) < 0.001 1.028 (1.015–1.040) < 0.001 1.028 (1.015–1.040) < 0.001 1.029 (1.017–1.042) < 0.001 Weight————————0.997 (0.988–1.006)0.4870.997 (0.988–1.006)0.520 0.997 (0.988–1.006) 0.570Concomitant moderate to strongCYP2D6 inhibitors——————————1.027 (0.715–1.476)0.885 0.968 (0.673–1.392) 0.859Concomitant heart rate‐lowering drugs——————————1.585 (1.156–2.172) 0.004 1.393 (1.000–1.940) 0.050History of MI———————————— 1.740 (1.317–2.298) < 0.001 History of HF———————————— 1.737 (1.277–2.364) < 0.001 History of HTN———————————— 1.104 (0.782–1.559) 0.573History of AF/flutter———————————— 1.365 (1.030–1.810) 0.031 Note: Bold highlights asociations with p < 0.05.Abbreviations: 95% CI, confidence intervals of 95%; AF, atrial fibrillation; CYP2D6, cytochrome P450 2D6; HF, heart failure; HR, hazard ratio; HTN, hypertension; MI, myocardial infarction. Associations between CYP2D6 genotype‐inferred metabolizer status and all‐cause mortality. 0.902 (0.747–1.088) 0.914 (0.756–1.105) 0.842 (0.694–1.020) 0.816 (0.673–0.991) 1.004 (1.002–1.006) 1.004 (1.002–1.006) 1.003 (1.002–1.005) 1.072 (1.052–1.092) 1.074 (1.053–1.095) 1.076 (1.055–1.097) 0.609 (0.442–0.839) 0.711 (0.512–0.985) 1.028 (1.015–1.040) 1.029 (1.017–1.042) 0.997 (0.988–1.006) 0.968 (0.673–1.392) 1.393 (1.000–1.940) 1.740 (1.317–2.298) 1.737 (1.277–2.364) 1.104 (0.782–1.559) 1.365 (1.030–1.810) Note: Bold highlights asociations with p < 0.05. Abbreviations: 95% CI, confidence intervals of 95%; AF, atrial fibrillation; CYP2D6, cytochrome P450 2D6; HF, heart failure; HR, hazard ratio; HTN, hypertension; MI, myocardial infarction. Metoprolol Concentrations The results for unadjusted and fully adjusted models are presented in Table 2. The unadjusted crude model showed a significant association between mortality and increasing metoprolol concentrations (HR = 1.002 [95% CI: 1.001–1.003]; p < 0.001). Yet, when adjusting for baseline characteristics, metoprolol concentrations were no longer significant (HR = 1.001 [95% CI: 1.000–1.002]; p = 0.07). This is likely since patients in the highest quartiles presented more cardiac comorbidities, thus requiring higher metoprolol doses, were older, and that once adjusting for these confounders, higher concentrations were no longer associated with clinical outcomes (Table S3). Age, sex, heart rate, a history of myocardial infarction, HF, and atrial fibrillation or flutter were significantly associated with mortality. TABLE 2Associations between plasma Metoprolol tartrate concentrations and all‐cause mortality.VariablesModel 1Model 2Model 3Model 4Model 5Model 6Model 7HR (95% CI) p HR (95% CI) p HR (95% CI) p HR (95% CI) p HR (95% CI) p HR (95% CI) p HR (95% CI) p Plasma metoprolol tartrate concentrations1.002 (1.001–1.003) < 0.001 1.001 (1.000–1.002) 0.019 1.001 (1.000–1.002) 0.048 1.001 (1.000–1.002) 0.005 1.001 (1.000–1.002) 0.006 1.001 (1.000–1.002) 0.008 1.001 (1.000–1.002)0.069Metoprolol daily dose——1.003 (1.000–1.005) 0.048 1.003 (1.000–1.005) 0.032 1.002 (1.000–1.005)0.1081.002 (1.000–1.005)0.1021.002 (1.000–1.005)0.0931.002 (0.999–1.004)0.192Age————1.070 (1.051–1.090) < 0.001 1.076 (1.056–1.096) < 0.001 1.075 (1.055–1.096) < 0.001 1.073 (1.053–1.094) < 0.001 1.075 (1.054–1.096) < 0.001 Sex————0.637 (0.468–0.867) 0.004 0.604 (0.443–0.822) 0.001 0.595 (0.431–0.820) 0.002 0.582 (0.421–0.804) 0.001 0.693 (0.499–0.962) 0.029 Resting heart rate——————1.030 (1.017–1.043) < 0.001 1.030 (1.017–1.043) < 0.001 1.029 (1.017–1.042) < 0.001 1.030 (1.017–1.043) < 0.001 Weight————————0.999 (0.990–1.008)0.7510.999 (0.990–1.008)0.7520.999 (0.990–1.008)0.788Concomitant moderate to strong CYP2D6 inhibitors——————————1.013 (0.706–1.455)0.9430.954 (0.663–1.372)0.799Concomitant heart rate‐lowering drugs——————————1.530 (1.118–2.095) 0.008 1.385 (0.996–1.926)0.053History of MI————————————1.730 (1.309–2.288) < 0.001 History of HF————————————1.644 (1.203–2.247) 0.002 History of HTN————————————1.122 (0.796–1.583)0.511History of AF/flutter————————————1.342 (1.013–1.779) 0.041 Note: Bold highlights asociations with p < 0.05.Abbreviations: 95% CI, confidence intervals of 95%; AF, atrial fibrillation; CYP2D6, cytochrome P450 2D6; HF, heart failure; HR, hazard ratio; HTN, hypertension; MI, myocardial infarction. Associations between plasma Metoprolol tartrate concentrations and all‐cause mortality. Note: Bold highlights asociations with p < 0.05. Abbreviations: 95% CI, confidence intervals of 95%; AF, atrial fibrillation; CYP2D6, cytochrome P450 2D6; HF, heart failure; HR, hazard ratio; HTN, hypertension; MI, myocardial infarction. Discussion In the present study, we found that CYP2D6 genotype‐inferred metabolizer status was associated with all‐cause mortality in a cardiovascular cohort treated with metoprolol who were followed for a median of 101.4 months. Given that this association was of borderline significance, this finding warrants cautious interpretation. We found no significant association with metoprolol concentrations after adjusting for confounders. Our results are concordant with previous reports from our group and others demonstrating the associations between CYP2D6‐inferred metabolizer status and metoprolol concentrations, doses, and heart rate [8, 10, 16]. Our observation that patients with lower inferred CYP2D6 activity have a higher risk of mortality is novel. At first glance, it appears to contradict recent conclusions from a cohort of 1554 patients taking metoprolol succinate following myocardial infarction, in which no significant association with clinical events was observed [17]. Yet, results from this study still showed a trend toward higher all‐cause mortality in PM/IM compared to NM patients (HR = 1.45 [95% CI: 0.92–2.28]; p = 0.11), which is consistent with our findings. Of note, in that study, UM patients were removed from the analyses, metoprolol exposure was not assessed and, more importantly, the follow‐up was shorter (3 years) and the mortality rate was markedly lower relative to the MHI Hospital Cohort (5.5% vs. 24.3%), which may have limited their statistical power to detect a significant difference. The dose‐dependent risk of adverse drug reactions with beta‐blockers is well established. Moreover, multiple reports and meta‐analyses have proposed that a lower CYP2D6 metabolizing capacity and greater metoprolol exposure result in a greater reduction in heart rate and blood pressure which may result in a higher risk of bradyarrhythmias and hypotension [9, 18, 19, 20]. Thus, we hypothesized that the increased mortality risk we observed in patients with lower metabolizing capacity (PM and IM) could result from adverse hemodynamic consequences. Validation of this hypothesis is required, but is consistent with recommendations from CPIC guidelines. Indeed, current guidelines recommend initiating metoprolol at the lowest recommended dose for PM or using an alternative beta‐blocker to minimize the risks associated with greater blood pressure and heart rate reductions. Although these guidelines recognize that IM also present higher metoprolol concentrations compared to NM, but of a lower magnitude than PM, they indicate that current data is insufficient to determine whether metoprolol should also be more carefully initiated in IM. Collaborative efforts including multiple cohorts should be conducted to evaluate the association between CYP2D6‐inferred metabolizer groups and clinical outcomes in individuals receiving metoprolol to validate and to further explore our findings. Our investigation contains several strengths, such as the use of mortality, providing more direct evidence than pharmacokinetic or hemodynamic outcomes, as well as the long‐term follow‐up and large number of clinical events compared to previous investigations of metoprolol pharmacogenetics. Still, limitations inherent to observational biobank cohorts require cautious interpretation, such as the inclusion of prevalent metoprolol users, all of which were followed since their enrolment in the MHI Hospital Cohort rather than when metoprolol therapy was initiated. With recent CPIC guidelines suggesting that metoprolol PGx could predict the tolerability profile upon treatment initiation and titration [1], whether differences in long‐term clinical outcomes exist for new users remains challenging to assess when leveraging biobank participants. This includes deciphering the impact of metoprolol on heart rate from baseline heart rate, another limitation from our study. We also did not account for the use of metoprolol during follow‐up, which may have biased results toward the null. Moreover, our investigation was limited to participants of European ancestry, which limits the generalizability of our findings. As for all genetic association studies, replication of these results is warranted. In conclusion, this study provides supporting evidence that the CYP2D6‐inferred metabolizer status may predict survival in metoprolol users. Larger initiatives are required to properly determine if CYP2D6 genotype is associated with clinical events and whether, ultimately, preemptive genotyping can improve clinical outcomes. Author Contributions M.M., A.‐X.B., E.O., and S.D. wrote the manuscript; M.M., E.O., M.‐P.D., G.L., J.‐C.T., and S.D. designed the research; M.M., E.O., M.J., G.L., I.M., D.B., M.J., and J.‐C.T. performed the research; M.M., A.‐X.B., E.O., M.‐P.D., M.‐C.C., and S.D. analyzed the data; E.O., M.‐C.C., and S.D. contributed new reagents/analytical tools. Funding This work was supported by the Montreal Heart Institute Foundation and the Université de Montréal Beaulieu‐Saucier Chair in Pharmacogenomics (S.D.). J.‐C.T. and M.‐P.D. hold Canada Research Chairs. Conflicts of Interest S.D. reports grants outside the submitted work from AstraZeneca, and RMS/Dalcor. J.‐C.T. reports research grants from Boehringer‐Ingelheim, Ceapro, DalCor Pharmaceuticals, Merck, Novartis, Novo‐Nordisk, and Verve Therapeutics; honoraria from DalCor Pharmaceuticals, Merck, and Pendopharm; minor equity interest in DalCor Pharmaceuticals; and authorship of patents on pharmacogenomics‐guided CETP inhibition and on the use of colchicine after myocardial infarction. M.‐P.D. reports minor equity interest in Dalcor Pharmaceuticals; and authorship of patents on pharmacogenomics‐guided CETP inhibition and on the use of colchicine after myocardial infarction. All other authors declared no competing interests for this work. Supporting information Table S1: Baseline Cohort Characteristics According to CYP2D6 Pharmacogenetic Metabolizer Status. Table S2: Hazard ratios and 95% confidence intervals for all‐cause mortality comparing CYP2D6 NM/UM phenotypes with CYP2D6 PM/IM phenotypes. Table S3: Selected baseline characteristics according to metoprolol concentration quartiles. References Associated Data Supplementary Materials Table S1: Baseline Cohort Characteristics According to CYP2D6 Pharmacogenetic Metabolizer Status. Table S2: Hazard ratios and 95% confidence intervals for all‐cause mortality comparing CYP2D6 NM/UM phenotypes with CYP2D6 PM/IM phenotypes. Table S3: Selected baseline characteristics according to metoprolol concentration quartiles.